Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

The effectiveness of app-based mobile interventions on nutrition behaviours and nutrition-related health outcomes: A systematic review and meta-analysis.

Villinger K, Wahl DR, Boeing H, Schupp HT, Renner B.

Obes Rev. 2019 Jul 28. doi: 10.1111/obr.12903. [Epub ahead of print] Review.

PMID:
31353783
2.

Xenograft-based platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.

Zhao SG, Yu M, Spratt DE, Chang SL, Feng FY, Kim MM, Speers CW, Carlson BL, Mladek AC, Lawrence TS, Sarkaria JN, Wahl DR.

Neuro Oncol. 2019 May 23. pii: noz090. doi: 10.1093/neuonc/noz090. [Epub ahead of print]

PMID:
31121035
3.

Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy.

Zhang Q, Green MD, Lang X, Lazarus J, Parsels JD, Wei S, Parsels LA, Shi J, Ramnath N, Wahl DR, Pasca di Magliano M, Frankel TL, Kryczek I, Lei YL, Lawrence TS, Zou W, Morgan MA.

Cancer Res. 2019 Aug 1;79(15):3940-3951. doi: 10.1158/0008-5472.CAN-19-0761. Epub 2019 May 17.

PMID:
31101760
4.

Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma.

Kim MM, Speers C, Li P, Schipper M, Junck L, Leung D, Orringer D, Heth J, Umemura Y, Spratt DE, Wahl DR, Cao Y, Lawrence TS, Tsien CI.

J Neurooncol. 2019 Jun;143(2):313-319. doi: 10.1007/s11060-019-03166-3. Epub 2019 Apr 11.

PMID:
30977058
5.

No Sugar Added: A New Strategy to Inhibit Glioblastoma Receptor Tyrosine Kinases.

Wahl DR, Lawrence TS.

Clin Cancer Res. 2019 Jan 15;25(2):455-456. doi: 10.1158/1078-0432.CCR-18-2113. Epub 2018 Sep 4.

PMID:
30181388
6.

Combining Perfusion and High B-value Diffusion MRI to Inform Prognosis and Predict Failure Patterns in Glioblastoma.

Wahl DR, Kim MM, Aryal MP, Hartman H, Lawrence TS, Schipper MJ, Parmar HA, Cao Y.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):757-764. doi: 10.1016/j.ijrobp.2018.04.045. Epub 2018 Jun 2.

PMID:
29980414
7.

Casual Causality: Does Radiofrequency Ablation Really Prolong Survival After Treatment of Localized Hepatocellular Carcinoma?

Wahl DR, Schipper MJ, Parikh ND, Owen D, Lawrence TS.

J Clin Oncol. 2018 Aug 20;36(24):2559-2560. doi: 10.1200/JCO.2018.78.0882. Epub 2018 Jun 26. No abstract available.

PMID:
29945526
8.

Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases.

Jackson WC, Tao Y, Mendiratta-Lala M, Bazzi L, Wahl DR, Schipper MJ, Feng M, Cuneo KC, Lawrence TS, Owen D.

Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):950-958. doi: 10.1016/j.ijrobp.2017.12.014. Epub 2017 Dec 15.

9.

Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.

Jackson WC, Tsien CI, Junck L, Leung D, Hervey-Jumper S, Orringer D, Heth J, Wahl DR, Spratt DE, Cao Y, Lawrence TS, Kim MM.

J Neurooncol. 2018 May;138(1):155-162. doi: 10.1007/s11060-018-2782-z. Epub 2018 Feb 1.

PMID:
29388034
10.

Healthy food choices are happy food choices: Evidence from a real life sample using smartphone based assessments.

Wahl DR, Villinger K, König LM, Ziesemer K, Schupp HT, Renner B.

Sci Rep. 2017 Dec 6;7(1):17069. doi: 10.1038/s41598-017-17262-9.

11.

PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.

Parsels LA, Karnak D, Parsels JD, Zhang Q, Vélez-Padilla J, Reichert ZR, Wahl DR, Maybaum J, O'Connor MJ, Lawrence TS, Morgan MA.

Mol Cancer Res. 2018 Feb;16(2):222-232. doi: 10.1158/1541-7786.MCR-17-0455. Epub 2017 Nov 13.

12.

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer.

Speers C, Zhao SG, Chandler B, Liu M, Wilder-Romans K, Olsen E, Nyati S, Ritter C, Alluri PG, Kothari V, Hayes DF, Lawrence TS, Spratt DE, Wahl DR, Pierce LJ, Feng FY.

NPJ Breast Cancer. 2017 Aug 18;3:29. doi: 10.1038/s41523-017-0038-2. eCollection 2017.

13.

Genomic-adjusted radiation dose.

Spratt DE, Wahl DR, Lawrence TS.

Lancet Oncol. 2017 Mar;18(3):e127. doi: 10.1016/S1470-2045(17)30092-X. Epub 2017 Mar 2. No abstract available.

PMID:
28271860
14.

Pan-Cancer Analysis of Genomic Sequencing Among the Elderly.

Wahl DR, Nguyen PL, Santiago M, Yousefi K, Davicioni E, Shumway DA, Speers C, Mehra R, Feng FY, Osborne JR, Spratt DE.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):726-732. doi: 10.1016/j.ijrobp.2017.01.002. Epub 2017 Jan 7.

PMID:
28258894
15.

Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.

Pollom EL, Lee K, Durkee BY, Grade M, Mokhtari DA, Wahl DR, Feng M, Kothary N, Koong AC, Owens DK, Goldhaber-Fiebert J, Chang DT.

Radiology. 2017 May;283(2):460-468. doi: 10.1148/radiol.2016161509. Epub 2017 Jan 3.

16.

Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis.

Wahl DR, Dresser J, Wilder-Romans K, Parsels JD, Zhao SG, Davis M, Zhao L, Kachman M, Wernisch S, Burant CF, Morgan MA, Feng FY, Speers C, Lyssiotis CA, Lawrence TS.

Cancer Res. 2017 Feb 15;77(4):960-970. doi: 10.1158/0008-5472.CAN-16-2008. Epub 2016 Dec 6.

17.

Translation of Targeted Radiation Sensitizers into Clinical Trials.

Reichert ZR, Wahl DR, Morgan MA.

Semin Radiat Oncol. 2016 Oct;26(4):261-70. doi: 10.1016/j.semradonc.2016.06.001. Epub 2016 Jun 2. Review.

PMID:
27619248
18.

Reply to Yang et al and De Bari et al.

Wahl DR, Tao Y, Schipper M, Lawrence TS, Feng M.

J Clin Oncol. 2016 Aug 10;34(23):2799. doi: 10.1200/JCO.2016.67.7492. Epub 2016 Jun 20. No abstract available.

19.

Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.

Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, Schipper MJ, Feng M.

J Clin Oncol. 2016 Feb 10;34(5):452-9. doi: 10.1200/JCO.2015.61.4925. Epub 2015 Nov 30.

20.

Integrating chemoradiation and molecularly targeted therapy.

Wahl DR, Lawrence TS.

Adv Drug Deliv Rev. 2017 Jan 15;109:74-83. doi: 10.1016/j.addr.2015.11.007. Epub 2015 Nov 18. Review.

PMID:
26596559
21.

2-Hydoxyglutarate: D/Riving Pathology in gLiomaS.

Wahl DR, Venneti S.

Brain Pathol. 2015 Nov;25(6):760-8. doi: 10.1111/bpa.12309. Review.

22.

Distinct metabolic programs in activated T cells: opportunities for selective immunomodulation.

Wahl DR, Byersdorfer CA, Ferrara JL, Opipari AW Jr, Glick GD.

Immunol Rev. 2012 Sep;249(1):104-15. doi: 10.1111/j.1600-065X.2012.01148.x. Review.

23.

Characterization of the metabolic phenotype of rapamycin-treated CD8+ T cells with augmented ability to generate long-lasting memory cells.

He S, Kato K, Jiang J, Wahl DR, Mineishi S, Fisher EM, Murasko DM, Glick GD, Zhang Y.

PLoS One. 2011;6(5):e20107. doi: 10.1371/journal.pone.0020107. Epub 2011 May 17.

24.

Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease.

Gatza E, Wahl DR, Opipari AW, Sundberg TB, Reddy P, Liu C, Glick GD, Ferrara JL.

Sci Transl Med. 2011 Jan 26;3(67):67ra8. doi: 10.1126/scitranslmed.3001975.

25.

Characterization of the metabolic phenotype of chronically activated lymphocytes.

Wahl DR, Petersen B, Warner R, Richardson BC, Glick GD, Opipari AW.

Lupus. 2010 Nov;19(13):1492-501. doi: 10.1177/0961203310373109. Epub 2010 Jul 20.

PMID:
20647250
26.

Apoptotic signaling activated by modulation of the F0F1-ATPase: implications for selective killing of autoimmune lymphocytes.

Sundberg TB, Swenson L, Wahl DR, Opipari AW Jr, Glick GD.

J Pharmacol Exp Ther. 2009 Nov;331(2):437-44. doi: 10.1124/jpet.109.156422. Epub 2009 Aug 25.

Supplemental Content

Support Center